Toshifumi Tsurusaki

Prognostic significance of β-microseminoprotein mRNA expression in prostate cancer

Human β‐microseminoprotein (β‐MSP or PSP94) is a small protein secreted by prostatic epithelial cells. We recently reported the presence of low levels of β‐MSP mRNA expression and protein in most prostate cancer tissues.

Cellular expression of beta-microseminoprotein (β-MSP) mRNA and its protein in untreated prostate cancer

Previous studies have shown that beta‐microseminoprotein (β‐MSP) may be used as a diagnostic marker for prostate cancer. However, the level of expression of β‐MSP in prostate cancer detected by immunohistochemistry (IHC) has varied from one study to another.

Hot Flashes During Androgen Deprivation Therapy With Luteinizing Hormone-Releasing Hormone Agonist Combined With Steroidal or Nonsteroidal Antiandrogen for Prostate Cancer

OBJECTIVES To investigate hot flashes and quality of life during combined androgen blockade (CAB) therapy using steroidal or nonsteroidal antiandrogens. METHODS A total of 151 patients with prostate cancer, who were enrolled into this study from May 2001 to June 2003, were randomized to receive CAB therapy using a luteinizing hormone-releasing hormone agonist (leuprorelin) combined with a steroidal antiandrogen (chlormadinone) or a nonsteroidal antiandrogen (bicalutamide). The incidence of, frequency of, and distress due to hot flashes were evaluated with a self-administered questionnaire during a 2-year period. The general and disease-specific quality-of-life outcomes were also measured using the Functional Assessment of Cancer Therapy-Prostate questionnaire. RESULTS Data were available for analysis from 124 patients. Although the incidence of hot flashes largely tended to be greater in the bicalutamide group than in the chlormadinone group, no significant difference was noted in the cumulative incidence of hot flashes at 2 years. The median frequency of hot flashes daily was 1.3 and 2.2 for warmth/flushing (P = .16) and 1.0 and 3.6 for sweating (P = .021) in the chlormadinone and bicalutamide groups, respectively. Patients in the chlormadinone group were significantly less likely to be distressed by warmth/flushing (odds ratio 0.47, P < .001) and sweating (odds ratio 0.61, P = .01) than were those in the bicalutamide group. The Functional Assessment of Cancer Therapy-Prostate scores over time showed no intergroup differences. CONCLUSIONS Our results suggest that CAB using a steroidal antiandrogen such as chlormadinone might induce fewer and less-distressing hot flashes than CAB with bicalutamide.

Influence of prior oral ethinylestradiol use on the efficacy of enzalutamide for the treatment of castration‐resistant prostate cancer in men

To elucidate the effect of prior use of ethinylestradiol on enzalutamide treatment for men with castration‐resistant prostate cancer.

Unicentric Castleman's disease with leiomyosarcoma: a rare association.

Abstract  A 54‐year‐old asymptomatic woman was first diagnosed with unicentric Castlemans disease at 51 years of age. The disease was identified incidentally behind the inferior vena cava after a computed tomography (CT) scan. She was followed conservatively and no enlargement of the mass was observed. However, a follow‐up CT scan revealed another solid mass in the left retroperitoneal area. Both tumors were surgically removed in the same session. The retrocaval mass was histologically confirmed to be Castlemans disease of the hyaline vascular type. Histological examination of the left peritoneal mass revealed low‐grade leiomyosarcoma. We present here a case of leiomyosarcoma associated with unicentric Castlemans disease, both of which were localized in the retroperitoneum.